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Patients living with a spinal cord injury (SCI) often develop chronic neuropathic pain 
(CNP). Unfortunately, the clinically approved, current standard of treatment, gabapentin, 
only provides temporary pain relief. This treatment can cause numerous adverse side effects 
that negatively affect the daily lives of SCI patients. There is a great need for alternative, 
effective treatments for SCI-dependent CNP. 
Minocycline, an FDA-approved antibiotic, has been widely prescribed for the 
treatment of acne for several decades. However, recent studies demonstrate that minocycline 
has neuroprotective properties in several pre-clinical rodent models of CNS trauma and 
disease. Pre-clinical studies also show that short-term minocycline treatment can prevent the 
onset of CNP when delivered during the acute stage of SCI and can also transiently attenuate 
established CNP when delivered briefly during the chronic stage of SCI. However, the 
potential to abolish or attenuate CNP via long-term administration of minocycline after SCI 
is unknown. 
The purpose of this study was to investigate the potential efficacy and safety of long-
term administration of minocycline to abolish or attenuate CNP following SCI. A severe 
spinal contusion injury was administered on adult, male, Sprague-Dawley rats. At day 29 
post-injury, I initiated a three-week treatment regimen of daily administration with 
minocycline (50 mg/kg), gabapentin (50 mg/kg) or saline.  
[v] 
 
The minocycline treatment group demonstrated a significant reduction in below-level 
mechanical allodynia and above- level hyperalgesia while on their treatment regimen. After 
a ten-day washout period of minocycline, the animals continued to demonstrate a significant 
reduction in below-level mechanical allodynia and above-level hyperalgesia. However, 
minocycline-treated animals exhibited abnormal weight gain and hepatotoxicity compared to 
gapabentin-treated or vehicle-treated subjects.The results support previous findings that 
minocycline can attenuate CNP after SCI and suggested that minocycline can also attenuate 
CNP via long-term delivery of minocycline after SCI (36). The data also suggested that 
minocycline had a lasting effect at reducing pain symptoms. However, the adverse side 
effects of long-term use of minocycline should not be ignored in the rodent model.  
Gabapentin treatment caused a significant decrease in below-level mechanical 
allodynia and below-level hyperalgesia during the treatment regimen. Because gabapentin 
treatment has an analgesic effect at the concentration I administered, the results were 
expected. However, I also found that gabapentin-treated animals demonstrated a sustained 
reduction in pain ten days after treatment withdrawal. This result was unexpected because 
gabapentin has a short half-life of 1.7 hours in rodents and previous studies have 
demonstrated that pre-drug pain levels return shortly after withdrawal of treatment.  
Additionally, the gabapentin-treated animals demonstrated a significant and sustained 
increase in rearing events compared with all other treatment groups which suggested that 
gabapentin treatment was not only capable of reducing pain long-term but may also 
significantly improve trunk stability or improve motor function recovery.  
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 INTRODUCTION 
A traumatic spinal cord injury (SCI) can produce devastating and life changing 
neurological deficits. According to an extensive survey conducted in 2009 by the 
Christopher Reeve Foundation known as, One Degree of Separation, an estimated 1,275,000 
individuals in the United States suffer from the consequences of SCI (1). Aside from loss of 
motor function, chronic neuropathic pain (CNP) is one of the most prevalent problems 
reported among SCI patients. CNP is predominately defined as a state of long-term 
exaggerated pain that is brought about by alterations in the pain processing pathways within 
the central nervous system (CNS) and peripheral nervous system (PNS). This most often 
occurs as a result of disease or traumatic injury (2),(3),(4),(5). Neuropathic pain manifests 
into several types of evoked and non-evoked pain syndromes and significantly impairs the 
quality of life and functional recovery of SCI patients for the rest of their lives (6),(2). 
Unfortunately, CNP develops in 60%-80% of SCI patients (6),(7).  
Currently, there is no cure for CNP and it remains very difficult to treat despite a 
growing effort among researchers (8). Unfortunately, drugs prescribed for the treatment of 
CNP also cause numerous side effects and, at best, only temporarily relieves symptoms. SCI 
patients greatly need a new therapeutic intervention to inhibit CNP and improve their quality 
of life. This pre-clinical study will investigate and analyze the FDA-approved drug 
minocycline and its potential to reduce and possibly abolish established CNP after SCI. 
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Spinal Cord Injury 
 The United States has the highest number of SCI incidents worldwide, with 
approximately 12,400 new cases each year (9). The leading causes of SCI in the United 
States are motor vehicle accidents (50%), falls (16%), violent acts (12%) and sports related 
injuries (10%) (9). Males are much more likely to acquire SCIs and account for nearly 80% 
of all new cases (9). After SCI, patients endure a lifetime of complications such as 
neuropathic pain and psychosocial issues in addition to permanent disabilities such as 
muscle spasticity and paralysis (7),(10),(11). Unfortunately, several incompletely 
understood mechanisms contribute to the wide array of problems associated with SCI. There 
are no FDA-approved treatments to restore function after SCI and treatments to relieve 
associated symptoms are often insufficient and temporary. Muscle spasticity, a common 
secondary problem after SCI may also be linked to a condition called autonomic dysreflexia 
which is reported most often when the insult occurs at the fifth and sixth thoracic segments 
(12),(13). Autonomic dysreflexia is a severe and debilitating condition characterized by a 
rapid attack that causes an enormous increase in blood pressure, shivering, sweating, anxiety 
and severe headaches (13).  
In addition to enduring the life-changing physical consequences of SCI, the financial 
burden for treating the numerous chronic conditions is often overwhelming.  Patients usually 
take medication, undergo years of physical rehabilitation and require caregivers and medical 
devices to help them perform daily functions. Healthcare costs for SCI patients during the 
first year of injury can range from $228,000 to $775,000 and cost up to three million dollars 
during their lifetime (1).  
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The consequences of SCI can vary depending on the severity and location of impact 
on the spinal cord. In moderate to severe cases, pathophysiology begins with a primary 
injury caused by direct mechanical insult to the spinal cord and is followed by a prolonged 
secondary injury phase where damage continues to occur. Primary injury is often due to 
contusion and compression forces which are caused by bone and/or disk fragments that 
bruise the spinal cord upon impact (14). During the first few hours after injury the patient 
may experience a variety of damaging pathological events such as edema, hemorrhaging, 
severing of white matter, shearing of blood vessels, and the formation of a necrotic epicenter 
(15).  
The secondary injury phase occurs days to weeks after injury and can often last years  
(15). The pathophysiology consists of ischemia and disruption of blood flow, ionic 
imbalances and demyelination, as well as degeneration of axons. Apoptosis of neuronal 
tissue, infiltration of peripheral immune cells such as T-cells, neutrophils and macrophages, 
and formation of a glial scar also occur in response to injury (15).  The pathology of 
secondary injury can spread far beyond the necrotic epicenter over many years causing 
permanent damage to the tissue surrounding the area of injury and leading to an 
environment within the spinal cord that is unfavorable to growth and repair (16),(17).   
Figure 1, shown below, displays pathological events during the acute and chronic 
phase of injury. The events in the acute and chronic stage of SCI contribute to the permanent 
state of damage within the spinal cord that is highly unfavorable to growth and repair.  
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 Figure 1: Schematic presentation of the pathological events displayed during the acute and 
chronic phases of spinal cord injury. Adapted by permission from Macmillan Publishers 
Ltd: [Nature] copyright 2008 (18).  
One major consequence of SCI is a robust and prolonged inflammatory response. 
This complex response serves a dual role by providing both beneficial and deleterious 
effects during the acute and chronic phases of injury (15). This becomes a challenging issue 
for researchers working towards a treatment for the multitude of damaging consequences 
produced by SCI. Researchers work to provide a treatment or cure that will not only reduce 
neuronal death but will also promote regeneration of neurons and continue providing a 
neuroprotective environment for repair.  
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There are several cell populations involved in the process of inflammation after SCI 
including astrocytes, microglia, T-cells, neutrophils and monocytes (19). Cell populations 
function quickly to remove cell debris from the lesion site and attempt to create an 
environment suitable for re-growth of tissue. Meanwhile, other cellular populations 
counteract the response by advancing further tissue damage (20). 
A major aspect of secondary injury is inflammation. This greatly contributes to the 
death of neuronal tissue within the spinal cord (21). For example, resident microglia cells 
within the spinal cord can play a beneficial role by becoming activated after injury where 
they act as macrophages, removing deleterious and foreign debris (22). However, activated 
microglia also begin to release an excessive amount of  pro-inflammatory cytokines such as 
TNF-α and IL-1β, as well as reactive oxygen species, nitric oxide and proteases that 
continuously promote tissue damage within the spinal cord (21) Popovich and Jones, 2003; 
(22) Xu et al., 2001). Neurons and glial cell membranes produce arachidonic acid after 
CNS/PNS injury. This acid can release metabolic products such as prostaglandins, 
leukotrienes and free radicals that are largely associated with inflammation and neural 
toxicity (23),(24),(25),(26). Many recent studies stress the importance of targeting pro-
inflammatory molecules in the acute stages of SCI to prevent tissue damage that can occur 
as a result of the immune response (27),(28),(20).   
Fleming-Norenberg et al. found that activated microglia and macrophages were 
abundant up to one-year post-injury with analysis and histology of human cord tissue (20). 
Through microarray analysis of spinal cord tissue of rodents in the chronic phase of SCI, 
Nesic et al. discovered that there are many significantly up-regulated genes known to be 
involved in inflammation and increased expression of glial fibrillary acid protein (GFAP) 
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mRNA, a known marker of astrocytes (2).   Therefore, inhibiting neuro-inflammation is an 
important yet controversial approach for treating patients not only in the acute phase of 
injury, but also patients living in the chronic phase of SCI. 
Chronic Neuropathic Pain 
CNP is a highly prevalent and permanent condition among the SCI population and is 
known to affect patients with a moderate injury to patients with total paralysis. In a study of 
pain after SCI, it was reported that six months after injury 64% of patients complained of 
pain and 21% described the pain as severe (29). In a recent pain review after SCI, 64%-82% 
of patients reported painful sensations five years after SCI (30). CNP can occur above, 
below and at the site of injury. The onset of at-level neuropathic pain most commonly 
occurs within weeks of the initial injury, while the onset of below-level neuropathic pain 
occurs months to years after injury (7). There is no clear definition of when above-level pain 
appears in the patient population. It is most often  described as painful sensations when 
touching the face and an increase in sensitivity to cold and hot temperatures (31). 
Neuropathic pain can be characterized as spontaneous/non-evoked pain which is 
independent of peripheral stimuli or as peripherally-evoked pain which occurs when a 
stimulus is applied (7). Peripherally-evoked pain includes specific types of pain responses 
termed allodynia and hyperalgesia. Allodynia is described as a painful sensation in response 
to a normally non-painful stimulus (31). Hyperalgesia describes an exaggerated painful 
sensation in response to a stimulus that normally elicits a significantly reduced pain response 
(31). Phantom pain can also manifest in SCI patients with paralysis. Phantom pain is a type 
of spontaneous/non-evoked pain which causes patients to experience painful sensations 
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where all sensory input is gone (7). CNP syndromes are most often described by patients as 
persistent burning, cutting, stabbing, shooting, electrical and piercing pain (7),(31).  
Pain is a challenging area to study in humans due to the numerous classifications and 
questionnaires developed by researchers and multiple descriptions of pain by patients. In 
animal models, the task of measuring pain becomes even more difficult in addition to being 
highly controversial.  Von Frey hair filaments, thermal testing, and girdle response testing in 
a rodent model of SCI measure evoked pain. Researchers are currently unable to directly test 
spontaneous/non-evoked neuropathic pain in animals due to the absence of verbal 
communication. However, analysis of spontaneous exploratory behavior utilizing a 
photobeam activity box can provide some insight into the development of non-evoked pain 
in animal subjects.  
 The mechanisms of CNP are exceptionally complex and not entirely understood. 
However, recent studies have identified several contributing factors important for 
establishment and maintenance of neuropathic pain after SCI.  Neuronal mechanisms 
contribute to pain by inducing long-term plastic changes along the pain sensory pathways   
(32). Nociceptive signaling begins at peripheral sensory neurons enters the spinal cord 
dorsal horn, acting as the first relay for pain transmission (32). In a recent study of pain 
behavior in a rodent model of SCI coupled with electrophysiology data, the authors indicate 
that the peripheral sensory neurons become hyper-excitable after injury and contribute to an 
increase in pain sensation (4),(33). At the level of the spinal cord dorsal horn, increased 
glutamate release and prolonged activation of NMDA receptors also play a critical role in 
long-term plasticity of pain signals (34).  Electrophysiology studies show “central 
sensitization” of the spinal dorsal horn neurons correlates with an increased pain response 
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after SCI (35),(36). The combination of both sustained hyper-excitability of peripheral 
neurons and hyper-sensitization of central neurons sends a robust, amplified response to the 
thalamus (33). The intensified sensory interpretation by the thalamus of all the combined 
neuronal signals is pain (33). 
Studies also suggest that synaptic reorganization such as sprouting in the dorsal horn 
occurs after SCI (37). Sprouting of dorsal horn neurons can lead to permanent neuronal 
changes and can also amplify pain signal pathways leading to the thalamus 
(33),(38),(36),(39). Evidence suggests that changes can also occur in third-order somato-
sensory neurons (33),(40).  Hyper-excitability of thalamic VPL neurons suggests that there 
is major reorganization of the synaptic circuits and neuronal pathways after SCI (40).  
Furthermore, glial cells, which are normally in an inactive/resting state in healthy 
individuals, work to maintain the architecture and homeostasis of neuronal cells within the 
spinal cord (41). However, upon activation due to SCI, glial cells (astrocyte and microglia 
subtypes)  increase in cell volume, become thickened and display characteristic “ramified 
branches” (41),(36). Permanent activation leads to increased proliferation of glial cells and a 
continuous up-regulation of  inflammatory cytokine release (41). Once activated, astrocytes 
and microglia contribute to CNP through persistent hyper-excitability of the spinal dorsal 
horn neurons (2),(35). Chronically activated microglia produce pro-inflammatory mediators 
such as IL-1-β, TNF-α, IL-6, MMP-9, MCP-1, TIMP-1 and reactive oxygen species that 
contribute to the development and maintenance of CNP after SCI (42),(43),(36),(44).     
Evidence from authors of animal studies indicates a strong correlation between pain 
sensations and pro-inflammatory mediators released by microglia cells after SCI. For 
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example, TNF-α and IL-1β contribute to the development of mechanical allodynia after SCI, 
and IL-6 contributes to maintenance of mechanical allodynia (42). The macroglial cells, 
astrocytes, are also important in the maintenance and development of pain after SCI. 
Astrocytes, in an inactive state and healthy state, provide infrastructure and homeostatic 
control of neurotransmitters outside of the synaptic cleft (45). Activated astrocytes 
contribute to pain after SCI in numerous pre-clinical studies of CNP after SCI. For example, 
Crown et al. provided strong evidence that astrocytes, as well as microglia, have increased 
expression of p-38 MAPK enzymatic activity in a rat model of SCI (44). The increased 
expression of p-38 MAPK after SCI in the astrocytic cell population plays an important role 
in the development of CNP. Inhibition of p-38 MAPK correlates with a decrease in CNP as 
well as improved locomotor recovery after SCI (44). 
Glial cells also prevent down regulation of GAD-65 in the spinal dorsal horn (35). 
This suggests that there is a decrease in endogenous inhibitory activity, which could 
contribute to hyper-excitability found in the neuronal pathways. The term “gliopathy” is 
now used to describe the many maladaptive responses of glial cells after neural injury (45). 
Recent evidence suggests that inhibition of glial activation in both astrocytes and microglia 
improves the outcome of chronic pain development  with early intervention in animal 
models of SCI (28),(46),(44). 
Treatment  
 As previously stated, there is no cure for CNP and treatment with common analgesic 
drugs is highly inadequate at reducing pain (8). The current, clinically approved treatment 
for CNP is gabapentin (47). Gabapentin was developed for the treatment of seizures and is 
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labeled as an anti-convulsant  drug (48). The mechanism of action is still unclear. However, 
recent studies have demonstrated that gabapentin binds to a calcium channel subunit, alpha -
2-delta, and reduces calcium influx into cells (49). The reduction of calcium may contribute 
to a decrease in excitability by inhibiting transmitters such as glutamate and substance P in 
neurons and therefore provides an analgesic effect (50),(51). In a recent study, gabapentin 
treatment reduced symptoms of autonomic dysreflexia and muscle spasticity in a rodent 
model of SCI. The authors indicated that gabapentin administration (50 mg/kg), two to three 
weeks after injury reduced spinal motor reflexes and dysreflexic hypertension (12). The 
findings suggest that gabapentin may be producing an effect through more than one 
pathway. Therefore, in SCI patients it is beneficial for attenuating pain, but may also be able 
to attenuate muscle spasticity and autonomic dysreflexia. Unfortunately, clinical studies 
indicate that patients often discontinue use due to the numerous adverse side effects such as 
dizziness, confusion, sedation, cost and lack of efficacy (52),(53). Pregabalin, an alternative 
to gabapentin, is also currently being used for treatment of CNP (54). Recent clinical studies 
have shown pregabalin to be more effective at a lower dosing regimen than gabapentin (54). 
However, side effects such as dizziness and somnolence are reported in approximately 30% 
of patients (54). Side effects of drugs prescribed for CNP should be minimal because they 
can negatively affect patients’ already difficult daily activities and further reduce their 
quality of life.  
Previous drugs used for treatment of CNP, such as methylprednisolone, have proven 
to be ineffective in clinical trials (55). Opioids such as morphine and oxycodone are also 
used by patients to relieve pain symptoms (48). However, abuse of opioid drugs is common 
and most are considered highly addictive, both physically and psychologically (56). 
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Tolerance to opioid drugs occurs rapidly and withdrawal is often a challenge for chronic 
users (56).  Therefore, opioid drugs are not a primary source of treatment for chronic pain 
syndromes associated with CNP. Based on the lack of efficacy and safety of current pain 
treatments, novel therapies with minimal or no adverse side effects need to be found for 
patients in the chronic stage of SCI who are living with CNP.  
 Interestingly, several pre-clinical SCI studies have not only shown that neuro-
inflammation is an important mechanism in the development and maintenance of CNP; 
these studies have also demonstrated that there is a significant correlation between 
inflammation and neuropathic pain (33),(42),(43). A potentially promising drug to inhibit 
CNP in the chronic stages of SCI is an anti-inflammatory drug called minocycline, which 
has been FDA-approved since 1971, initially for the treatment of acne (57). Minocycline is a 
semi-synthetic, second generation tetracycline antibiotic (58). Importantly, minocycline is a 
highly lipophilic molecule allowing it to pass easily through the blood-brain barrier (58). 
Access to the blood-brain barrier may be necessary for targeting inflammation that arises 
within the CNS. Because CNP likely involves interconnecting pain-processing pathways in 
both the CNS and PNS, access to the blood-brain barrier may be imperative when 
developing a therapeutic intervention. 
Minocycline as a therapeutic agent has become increasingly important due to 
efficacy in pre-clinical animal studies and clinical studies treating neurodegenerative 
diseases such as ischemia, multiple sclerosis, amyotrophic lateral sclerosis, acute and 
chronic spinal cord injury, Huntington’s disease, Parkinson’s disease and Alzheimer’s 
disease (58). Minocycline exhibits the ability to be a potent anti-inflammatory and anti-
apoptotic agent (58),(59). The anti-inflammatory action occurs by minocycline’s ability to 
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inhibit activation of microglia and in turn inhibit the release of many pro-inflammatory 
cytokines (59). Minocycline also reduces inflammation by inhibiting matrix 
metalloproteinases (MMP), whose enzymatic activities are involved in the breakdown of 
extracellular matrix and tissue remodeling (60). In addition, minocycline has the capability 
of being neuroprotective by preventing apoptosis of neuronal cells through inhibition of 
cytochrome-c release from the mitochondria (61),(62).  
Previously, clinicians prescribed minocycline for its known antimicrobial activity 
and effectiveness against gram-positive and gram-negative infections (63). In more recent 
years, minocycline has been used in clinical trials for neurodegenerative diseases such as 
acute stroke, acute SCI, and ALS (58). Minocycline is safe and effective for the treatment of 
rheumatoid arthritis. Currently, minocycline is prescribed by 18% of rheumatologists for 
rheumatoid arthritis (64). Minocycline use for treatment of diseases is becoming 
increasingly popular.  
 In several pre-clinical studies of acute CNS trauma and disease, minocycline has 
been proven to be effective in reducing pain symptoms and improving functional recovery 
(65),(36),(66),(67),(28),(46). Hains and Waxman et al. showed that minocycline treatment 
five days post-injury in a rat model of contusion injury improved  pain thresholds using 
behavioral assessment over a four week time period (28). Hains and Waxman also found 
that minocycline can improve pain withdrawal thresholds after CNP has been established 
with a three day dosing regimen of minocycline in a one month post-SCI rat model (36). 
While the improvements in pain threshold were shown during the three day dosing regimen 
the pre-drug levels of pain returned immediately after withdrawal of minocycline (36). It is 
[12] 
 
currently unknown whether long-term administration of minocycline could be beneficial in 
reducing or abolishing symptoms of CNP after SCI in a rodent model.  
The common side-effects of minocycline include skin complaints, nausea and 
dizziness (64). In general, minocycline has a reputation for being safe and well tolerated 
among patients who are administered the drug as an oral capsule. However, several case 
studies suggest that long-term use of minocycline have included rare, adverse side effects 
such as liver damage and autoimmune hepatitis that develop after an average of two years of 
use (68),(69),(70),(71),(72). Other studies have indicated rare side-effects such as black 
discoloration of the skin, bone and thyroid (73). Recent conclusions reported from a clinical 
study on the efficacy of minocycline in patients with amyotrophic lateral sclerosis were 
negative. Gordon et al. reported that ALS patients treated with minocycline for nine months 
declined more rapidly than those patients who received a placebo (74). Therefore, in future 
clinical studies it is important to be cognizant of the potential for adverse side effects that 
minocycline may cause, especially for long-term use in patients with CNS trauma or disease.  
I performed this study to investigate the potential efficacy and safety of long-term 
administration of minocycline to attenuate established CNP and to determine if pre-drug 
pain levels return after withdrawal of minocycline in a rat model of early chronic SCI.  
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SPECIFIC AIMS 
1. Determine whether minocycline can offer sustained relief of established CNP via 
long-term delivery.  
Using an adult, male, Sprague-Dawley rat model of spinal contusion injury, I 
determined whether minocycline could reduce established CNP over a long-term treatment 
period. A severe spinal contusion injury was administered at spinal thoracic level ten using 
200 kdyne of force. There was four treatment groups, (n=18); minocycline-treated, 
gabapentin-treated, vehicle- (saline) treated, and an uninjured, age-matched control group. 
Each group underwent direct and indirect neuro-sensory testing prior to SCI and every 2 
weeks for 60 days after SCI (day 0). At day 29, administration of either minocycline (50 
mg/kg), gabapentin (50 mg/kg), or vehicle (saline) began and continued daily for 3 weeks.  
 I assessed mechanical allodynia with von Frey hair testing of the hind limbs. Allodynia 
and hyperalgesia, above and below the level of injury were assessed with the girdle response 
test using von Frey filaments of non-noxious and noxious force. 
 A decrease in a variety of spontaneous behavioral activity can be a sensitive indicator of 
a non-evoked pain state. Therefore, I assessed exploratory locomotor behavior, which 
included fine and gross motor movement, time at rest, speed and distance using the 
photobeam activity system. The system was a completely objective and non-invasive tool. 
The animal subjects were allowed to move freely for 15 minutes, and then analysis of the 
software data  identified alterations in the behavioral tasks.  
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2. Determine whether CNP returns following withdrawal of minocycline 
administration.  
The potential of a minocycline treatment to cure CNP or to attenuate CNP via long- 
term delivery in SCI patients is currently unknown. At day 60, ten days after dosing was 
complete, I performed all direct and indirect neuro-sensory testing as previously described. I 
determined whether a sustained reduction of CNP had taken place beyond the conclusion of 
minocycline administration, which would indicate that minocycline treatment offered long-
term relief of established CNP. 
 
3. Compare the potential efficacy and safety of minocycline against gabapentin, the 
clinically approved compound used for treatment of CNP. 
Finally, I compared the efficacy and safety of minocycline to that of gabapentin, the 
current treatment for CNP by analyzing and comparing the minocycline treatment group 
to the gabapentin treatment group in all behavioral assessments and any additional 
observations made during the experiment. Both treatment groups received the same 
dosing regimen (daily for 3 weeks) and same concentration of drug (50 mg/kg) to make 
an equal comparison between treatment groups.  
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METHODS 
Animal Subjects 
I used adult, male Sprague-Dawley rats (225-249 grams) purchased from Harlan 
Laboratories, Houston, TX) for this study. The University of Texas Health Science Center 
Institutional Animal Welfare Committee approved all animal protocols. All lab members 
strictly followed the procedures for laboratory animal care and use found in the Institutional, 
AALAC, and NIH guidelines. Animal subjects were housed with access to food and water in 
the rodent facility at the Center for Laboratory Animal Medicine and Care (CLAMC) at the 
University of Texas Health Science Center at Houston. 
Surgery 
The surgeon anesthetized the animal subjects with an intraperitoneal (IP) injection of 
ketamine 80 mg/kg, zylazine 10 mg/kg, acepromazine 0.75 mg/kg before the animals 
underwent a laminectomy at the tenth thoracic (T10) spinal segment. Next, the surgeon 
administered a “severe” contusion injury with the Infinite Horizons Spinal Impactor device 
(Precision Systems and Instrumentation) using 200 kdynes of force and zero dwell time. The 
injury model is a successful and well-validated model in the literature and defined by Dr. 
Nesic-Taylor at UTMB-Galveston. The surgeon completed the procedure by suturing the 
muscle layers together and used surgical staples to secure the skin closed.  After surgery, the 
animal subjects recovered on heating pads overnight. I administered 3.0 mL subcutaneous 
saline injections to prevent dehydration. Animal subjects also received subcutaneous 
injections of Baytril (2.7 mg/kg) twice daily for ten days to prevent post-operative infection 
and subcutaneous injections of the analgesic buprenorphin (0.1 mg/kg) were administered 
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twice daily for five days post-injury. Animals were closely monitored and provided with the 
appropriate palliative care including manual bladder expression which was performed twice 
daily for approximately 15 days post-injury until reflex bladder function returned.  
Drug Administration 
Twenty-nine days post-SCI, I divided the injured animals into three treatment 
groups. One treatment group (n=18) received a 3 mL IP injection of 0.9% sodium chloride 
solution daily for 3 weeks. The second SCI group (n=18) received a 3 mL IP injection of 
minocycline (50 mg/kg) daily for 3 weeks beginning at day 29 post-injury. Stock solutions 
of minocycline hydrochloride  ( 7 mg/mL; molecular weight (MW) of 538.98; TOCRIS 
Biosciences, Ellisville, MO) were prepared in 0.9% sodium chloride solution, gently 
warmed in a 60° C water bath for 15 minutes, vortexed, and stored at 4° C for use within 2 
days. The third SCI group (n=18) received a 2 mL subcutaneous injection of gabapentin (50 
mg/kg) daily for three weeks beginning at day 29 post-injury. A stock solution of gabapentin 
(10mg/mL; MW=171.2; Santa Cruz, Santa Cruz, CA) was prepared fresh daily by diluting 
in 0.9% sodium chloride solution and briefly mixing. The dose concentrations were based on 
previously published studies by Hama and Sagen, who described the effectiveness of 
gabapentin in reducing pain after SCI (75). In order to make experimental comparisons 
between the effectiveness of minocycline and gabapentin, I used the same concentrations for 
both treatment groups. A naïve control group (n=18) was also included in this study to 
compare to the injured animals and observe the normal behavior trends in non-injured, age-
matched control animals.  
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Hind Limb Locomotor Functional Assay 
Recovery of locomotor function following SCI was recorded using the BBB 
locomotor rating scale developed by Drs. Basso, Beattie and Bresnahan at Ohio State 
University (76),(77). This scale allows the observer to rate hind limb motor function on a 
scale of “0,” no movement of hind limbs, to “21,” coordinated gait, while the animal moved 
freely in an open field for four minutes. This test ensured reliability of the injury model and 
assessed functional recovery of the animal’s hind limbs. Only animals that received a score 
of “0” or “1” at day one post-injury were included in the results of this study to ensure only 
animals of the same injury level were included.  
Von Frey Hair Test 
Mechanical allodynia was assessed by the application of von Frey filaments (3.61-
5.18) with increasing stiffness that corresponded to a gram of force applied (0.4 g-18 g) to 
the glabrous surface of the hind limb paws (refer to Figure 2B).  The animals were 
acclimated to the cages for two consecutive days (one hour per day) before baseline testing 
began and 30 minutes prior to all testing sessions. The filament was applied perpendicular to 
the paw with enough force to bend the filament slightly and held on the hind paw for one 
second. A positive response was recorded if the paw was removed immediately or licked 
(78),(79). If a positive response occurred, I allowed 30 seconds to pass before the next 
filament application. The Dixon up-down mechanical threshold protocol was used to 
determine the value at which the animal withdrew its paw 50% of the time for the left and 
right hind paws (80),(78). The value corresponded to the mechanical withdrawal threshold 
for each animal. Figure 2A, shown below displays the template for recording results of the 
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von Frey hair test using the Dixon up-down mechanical threshold protocol. A “0” indicates 
no movement and an “x” indicates a positive response. I averaged the values for the left and 
right hind paw together for a measure of withdrawal response at each time point. I 
performed this test prior to injury for a measure of baseline response and after injury at day 
14, day 28, day 42 and day 60. 
  
B
A 
Figure 2: (A) Example of a response recording for the left hind limb (on top) and right hind 
limb (on bottom) of one animal. Each number indicates an increasing stiffness and force of 
the filament from the lowest possible force of 3.61 to the highest force possible of 5.18; (B) 
Picture of a 4.13 von Frey filament  
 
 
Girdle response test 
At-level mechanical allodynia and at-level mechanical hyperalgesia were assessed 
using a 2-gram non-noxious force (allodynia) and a 26-gram noxious force (hyperalgesia) 
with the application of von Frey filaments on the body (81),(82). Prior to the initial baseline 
testing session, I allowed the animals to acclimate to the restraint device for 30 minutes for 
two consecutive days. I placed the animal subjects in a restraint device and allowed them to 
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acclimate for 20 minutes before each testing session began. The restraint device consisted of 
seven slits that allowed for easy application of the filaments  from left to right on the body at 
twelve different locations rostral to the level of injury and sixteen different locations caudal 
to the level of injury (Figure 3A). A positive response was an immediate flinching or 
vocalization after application of each filament (81),(82). I applied the 2-gram force first at 
each location on the body and the 26-gram force second. There was a 5 second delay 
between each application of the filament to allow the animal to relax between applications. 
The girdle response test was applied to each treatment group at baseline (before SCI), day 
14, day 28, day 42 and day 60 and responses were recorded on a grid map  (Figure 3B).  
 
 
A 
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Figure 3: Girdle Test Grid Map: (A)-A grid map of the body with black dots representing 
the location where the 2-gram (non-noxious) and 26-gram (noxious) von Frey filaments 
were placed above (12 locations) and below (16 locations) the level of injury. (B)Example of 
grid map recording session: “0” is no response, “X” is a flinch reaction, and “V” is a 
vocalization response. 
 
Photobeam Activity Box  
The photobeam activity box (PAS; San Diego Instruments, Inc) was comprised of 
four, clear plastic chambers (40 X 40 X 40 cm) with a series of 32 photo beams that line the 
chamber in both the x-axis and y-axis. PAS has been widely utilized to examine exploratory 
behavior of rodents in research studies. The system is a completely objective and non-
invasive tool for detecting fine and gross motor movements, rearing events, distance, speed 
and rest time of the animal subjects over a given period of time.  Alterations in locomotor 
activity can be used as a sensitive indicator of a pain condition (83),(84). However, I had to 
take special precautions when analyzing the data. For instance, a decrease in the distance 
traveled by the animal subject could indicate discomfort, illness or drowsiness due to the 
drug or a pain state. Therefore, it was critical to be consistent when handling the animals, 
standardize all procedures and carefully observe trends in all treatment groups and for each 
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animal over time before drawing conclusions regarding PAS results.  In this study, each 
testing session began at the same time each day (1pm) in a quiet room. I did not permit other 
animals or people in the room during active testing sessions. The chambers were cleaned 
with cavicide between each session which was important for removing “fear scents” that 
other animals could detect (85).  I set each animal gently inside each chamber and allowed 
to move freely for a total of 15 minutes. The animal’s movement in the x, y and z planes 
caused an obstruction in the beam breaks. A software database collected the various 
obstructions made by the animal’s movement for analysis.  
I assessed all treatment groups at baseline (before SCI), day 14, day 28, day 42 and 
day 60 post-SCI.  I assessed the distance (centimeters) the animals moved, the average speed 
at which the animals traveled (cm/sec), the amount of time the animals were active 
(seconds), the total amount of ambulatory movements and the total amount of rearing events 
the animals performed during their 15 minutes in the chamber.  
Histology 
The animals were sacrificed using a 100 mg/kg IP injection of pentobarbital, and a 
trans-cardial perfusion was performed using approximately 150 mL of ice-cold buffered 
saline with heparin (20 mg/500 mL) followed by perfusion with approximately 300 mL of 
4% paraformaldehyde solution. I then dissected the liver from several animal subjects and 
placed it in a 50 mL conical tube filled with 4% paraformaldehyde solution for 24 hours and 
placed the liver in a 50 mL conical tube filled with 30% sucrose solution for storage at 4° C. 
I cut liver sections on a cryostat machine with a thickness of 30µm per section and placed 
the sections into tris-buffered saline (TBS) solution. The tissue sections were carefully 
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mounted onto subbed glass slides and allowed to dry overnight. I then performed a 
hematoxylin-eosin (HE) stain by rinsing slides in distilled water for 2 minutes, staining in 
hematoxylin (cat#MHS-128; Sigma Aldrich) for 15 minutes followed by rinsing each slide 
in distilled water. The slides were decolorized in acid alcohol for 3 seconds followed by 15 
minutes of rinsing in tap water. The slides were counterstained with 10 dips in eosin solution 
(cat# 152880250; Acros Organics), dehydrated with a series of ethanol solutions, cleared 
with Hemo-D solution, mounted with Cytoseal solution and cover slipped.  
I used the Masson’s trichrome for connective tissue kit (cat#26367; Electron 
Microscopy Sciences) for staining liver tissue sections. The protocol was performed 
according to Sheehan and Hrapchak: Theory and Practice of Histotechnology (St. 
Louis.1980, p. 190) with slight modifications to the incubation times to optimize color 
saturation.  
Immunohistochemistry 
Liver tissue sections of 30 µm thickness from the vehicle group (n=1) and 
minocycline group (n=2) were incubated for 1 hour at room temperature in a blocking 
solution made of TBS (tris-buffered saline) with 0.25% triton containing 5% normal donkey 
serum (Jackson Immuno Research 017-000-121). The sections were then incubated 
overnight at 4° C in a primary antibody solution. This solution consisted of TBS with 0.25% 
triton solution with goat anti- IL-1β (1:1000, R&D Systems) and mouse anti-ED-1/CD-68 
(1:500, AbD Serotec). The sections were washed with three rinses of TBS and then placed in 
a secondary antibody solution for 3 hours at room temperature. The secondary antibody 
solution consisted of TBS with 0.25% triton, Alexa-Fluor 488 donkey anti-goat IgG, H+L 
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(1:500, Invitrogen), and Alexa-Fluor 568 donkey anti-mouse IgG (1:500, Invitrogen). The 
sections were washed with 3 rinses of TBS and mounted onto subbed glass slides and 
allowed to dry overnight. The dried tissue sections were then coverslipped with Fluormount-
G (Fisher).  
Statistical analysis 
All behavior data was normalized to each animal’s baseline score (% baseline) to 
reduce animal to animal variability. Statistical analysis was performed using Sigma Plot 
software with a repeated-measures two-way ANOVA test and Holm-Sidak pairwise-
comparisons. 
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RESULTS 
The Basso, Beattie and Bresnahan (BBB) locomotor test was performed on each 
animal at day 1, 2, 3, 5, 7 and 14 post-injury to verify that a severe contusion injury was 
properly administered (76). The results indicate the naïve-uninjured animals (n=18) scored a 
mean of 21 ± 0 at all time points tested. A score of 21 means the animals had normal 
locomotor function and gait, which was expected in naïve un-injured animals. Beginning 
one day post-injury BBB scores were significantly decreased compared to the naïve animals 
(p=0.001), confirming that a severe contusion injury was properly administered in the 
majority of the injured animals (Figure 4). The injured animals scored a mean of 0.6 ± 1.7 at 
day one post-injury, which means the animals had either no hind limb movement or slight 
movement of one joint. Over time, the injured animals developed slight locomotor recovery 
of the hind limbs indicated by an increase in score at day 14 with a mean of 11.1 ± 1.9. This 
score means the animals had frequent to consistent plantar steps with no forelimb, hind-limb 
coordination.
[25] 
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Figure 4: The BBB locomotor rating scale shows there was no change in the un-injured 
naïve group (n=18) over time. The injured animals (n=56) show a significant decrease in 
hind limb motor function at day 1,2,3,5,7,10 and 14 after injury compared to the naïve 
animals ( * p =0.001 vs. naive). Error bars represent mean ± standard deviation (SD). 
 
 
In order to establish the development of CNP after injury, the animals were subjected 
to a series of behavior testing sessions prior to SCI to determine baseline scores and then 
again at day 14 and 28 after injury. Approximately 70% of the animals developed pain by 
day 28 post-injury.  SCI animals that did not develop pain were excluded from the study, 
meaning any animals performing as well or better than they did before injury were excluded. 
It was critical to assess only the animals that developed pain prior to treatment in order to 
assess treatment-dependent effects on pain. The results of all behavior data were normalized 
to each animal’s baseline score following the exclusion of animals that did not develop pain 
to reduce animal-to-animal variability. Because of the exclusionary criteria, the number of 
animals per group was; naïve (n=18); vehicle group (n=12); minocycline group (n=13); 
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gabapentin group (n=13).  The final exclusion criteria to eliminate non-pain developing 
animals are listed in Table 1.  
 
Test Reason # of animals 
BBB score ≥ score 2 at day 1 4 
Von Frey Test Data ≥ 100% of baseline at day 14 and 28 2 
Von Frey Test Data ≥ 200% of baseline at day 14 or 28 1 
Von Frey Test Data ≥ 300% of baseline at any time point 4 
Von Frey, Girdle and PAS 
Data outlier at multiple time points in data 3 
Von Frey and Girdle Data outlier at multiple time points in data 2 
Girdle and PAS Data outlier at multiple time points in data 1 
Total Excluded From Study 
17 of 56 
animals 
 
Table 1 Exclusion Criteria: Animals that showed lack of pain development after examining 
all behavior data were excluded from this study. Seventeen of 56 injured animals were 
excluded, which resulted in pain development in 70% of all injured animals (n=56).  
 
Behavior Testing Results  
A. Von Frey Hair Test 
Below-level mechanical allodynia was measured by the von Frey hair test. The test 
was performed by touching von Frey filaments with increasing grams of force (0.4-15 g) 
to the glabrous surface of the left and right hind paw for one second. An immediate 
withdrawal of the paw or licking of the paw was recorded as a positive response. After 
injury (day 14 and day 28), there was a significant decrease in the force required to 
induce a positive response compared with baseline scores (p< 0.003; Figure 5). Before 
injury, all of the injured animals demonstrated a relatively high withdrawal threshold 
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(group mean of 13.8 g ± 5.1 g). After injury, the withdrawal threshold decreased by day 
28 (group mean of 5.8 ± 3.6 g). The sensitivity to a lower gram of force required to 
induce a positive response indicated the onset of below-level mechanical allodynia. The 
naïve un-injured group showed a slight decrease in withdrawal threshold at day 28 and 
day 42; however, these results were not significant. After two weeks of daily dosing, the 
von Frey hair test was performed again (day 42 testing). Minocycline and gabapentin 
significantly increased withdrawal threshold compared to day 14 and day 28 (p<0.007; 
minocycline group mean 10.2 ± 5.5 g; gabapentin group mean 9.7 ± 4.8 g). The 
withdrawal threshold remained at the same significantly increased level by day 60 
compared to day 14 and day 28 (p <0.007; minocycline group mean 10.6 ± 3.9 g; 
gabapentin group mean 9.9 ± 3.6 g). The injured vehicle group did not display an 
increase in withdrawal threshold at any time point and clearly demonstrated significantly 
reduced withdrawal thresholds from day 14 to day 60 compared to baseline (p<0.005; 
day 42 vehicle group mean 4.5 ±1.6 g; day 60 vehicle group mean 6.9 ±3.6 g).  
[28] 
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Figure 5 Below-level mechanical allodynia: von Frey hair test calculated with the up-
down Dixon method. Minocycline and gabapentin resulted in a significant increase in 
withdrawal threshold 2 weeks after treatment (day 42) and 10 days after cessation of the 
drug (day 60). Error bars display the mean ± SEM. [(*) p<0.005 vs. baseline; 
     (†) p <0.015 vs. naïve; (#) p <0.007 vs. day 14/28; (##) p <0.005 vs. vehicle] 
 
B. Girdle Response Test 
Hyperalgesia and allodynia were measured with the girdle response test on the torso 
of the animal below and above the level of injury while stabilized in a girdle restraint 
device. Hyperalgesia was measured with a 26-gram von Frey filament. The 26-gram 
filament was considered a noxious force to the animals and was applied to the body until 
the filament slightly buckled.  Allodynia was measured with a 2-gram von Frey filament. 
The 2-gram filament is considered a non-noxious/non-painful force. First, the 2-gram 
filament was applied as previously described on the animal at sixteen locations below 
the level of injury (T10) from left to right and twelve locations above the level of injury 
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from left to right. Positive responses were noted as a flinch or vocalization and then 
recorded on a grid map. Following the 2-gram force the same procedure was repeated 
with the 26-gram force. An increase in the percentage of positive responses after injury 
indicated pain development.  
The results demonstrate that there was no significant increase in response above the 
level of injury when compared to the baseline using the 2-gram von Frey filament. 
Therefore, there was no verifiable allodynia demonstrated at day 14 and day 28 above 
the level of injury with this test (Figure 6). The naïve group had a significant decrease in 
response at day 42. 
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Figure 6 Allodynia above the level of injury: There was no increase in positive 
responses with a 2-gram force applied above the level of injury in the vehicle, 
minocycline or gabapentin treatment groups. The naïve group’s response significantly 
decreased compared to day 14. Error bars display the mean ± SEM. (# p =0.002 vs. day 
14). 
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There was no significant increase in positive responses below the level of injury 
using the 2-gram von Frey filament at day 14 and day 28 (Figure 7). Therefore, there 
was no demonstration of allodynia below the level of injury with the girdle response test. 
At day 60, the vehicle treatment group and gabapentin treatment group demonstrated a 
significant decrease in positive responses when compared to day 14 and day 28 
(p<0.004). 
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Figure 7 Allodynia below the level of injury: There was no increase in positive 
responses below the level of injury with 2 grams of force. At day 60, all animal groups 
had decreased positive responses. There was a significant decrease in the vehicle and 
gabapentin treatment groups at day 60. Error bars display the mean ± SEM. (# p < 
0.004 vs. day 14/28). 
 
There was a significant increase in positive responses after injury with application of 
the 26-gram von Frey filament above the level of injury at day 14 in all injured animal 
groups compared to baseline (p <0.004, Figure 8). The minocycline treatment group 
[31] 
 
also demonstrated a significant increase at day 28 (p=0.003). The vehicle and 
gabapentin group demonstrated an increased response at day 28; however, it was not 
significant. At day 42 of testing, 2 weeks of treatment with minocycline caused a 
significant decrease in positive responses when compared to day 14 (p=0.005).This 
result was not achieved in either the gabapentin or vehicle group. By day 60, ten days 
after dosing was complete (washout period), the minocycline-treated animals continued 
to demonstrated a significant decrease in positive responses when compared to day 14 
and day 28 (p<0.001). The vehicle group also demonstrated a significant decrease in 
positive responses at day 60 compared to day 14 (p=0.002), the positive responses were 
still 50% greater than the baseline. No significant decreases in positive responses were 
demonstrated with the 26-gram force in the gabapentin-treated animals. 
 
[32] 
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Figure 8: Hyperalgesia above the level of injury: There was a significant increase in 
positive responses in the SCI animals after injury at day 14. Only the minocycline group 
had significantly decreased responses with treatment that remained through day 60. 
Error bars display the mean ± SEM. [(*) p<0.004 vs. baseline; (†) p <0.007 vs. naïve; 
(#) p <0.006 vs. day 14/28] 
 
Positive responses increased at day 14 and day 28 in all injured animals compared to 
baseline with application of the 26-gram force von Frey filament below the level of injury 
(Figure 9). However, only the vehicle and gabapentin treatment groups demonstrated 
significantly increased positive responses at day 14 and day 28 compared to baseline 
(p<0.004). After two weeks of treatment with minocycline (day 42), positive responses did 
not significantly increase. The vehicle group did not show a significant decrease in response 
at any testing session. However, two weeks of gabapentin treatment significantly reduced 
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positive responses at day 60, 10 days after treatment was complete (washout period) when 
compared to day 14, day 28 and day 42 testing sessions (p<0.009).  
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Figure 9 Hyperalgesia below the level of injury: There was no significant increase in 
response in the minocycline group and no significant change after treatment. The vehicle 
and gabapentin groups demonstrated significantly increased responses to the 26-gram 
force after injury at day 14 and day 28. The gabapentin group had a significant decrease 
in positive responses at day 60. Error bars display the mean ± SEM. [(*) p<0.004 vs. 
baseline; (#) p <0.009 vs. day 14/28] 
 
C. Photobeam Activity Box 
Animals were placed in a photobeam activity box for a total of 15 minutes during 
each behavior testing session. The activity box measured a series of locomotor behaviors 
in a software database for analysis of overall activity and fine and gross motor 
movements.  
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The distance that the animals moved throughout the chamber in 15 minutes was 
recorded in total centimeters. The naïve animals did not demonstrate any significant 
changes at any time point. However, all injured animals displayed significantly 
decreased distance in the chamber at day 14 (p<0.002, Figure 10). At day 28, the vehicle 
and minocycline-treated animals continued to show a significant decrease in total 
distance (p<0.002), while the gabapentin-treated animals did not demonstrate a 
significant decrease in total distance compared to baseline. Post-treatment (day 42 and 
day 60) minocycline did not increase total distance moved while gabapentin significantly 
increased at day 42 and day 60 compared to day 14 (p<0.005). However, the difference 
in total distance moved at day 42 and day 60 in the gabapentin group was not 
significantly different compared to day 28. The vehicle group demonstrated a significant 
increase in total distance moved at day 60 compared to day 14 (p=0.004), however it 
was also not significantly different when compared to day 28.  
[35] 
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Figure 10 Total Distance: There was not a significant increase in total distance in the 
minocycline group post-treatment. The gabapentin and vehicle group significantly 
increased total distance at day 60 compared to day 14. Error bars display the mean ± 
SEM. [(*) p<0.002 vs. baseline; (†) p <0.007 vs. naïve; (#) p <0.005 vs. day 14/28] 
 
 The average speed (cm/sec) the animals traveled in the activity box chamber was 
recorded throughout the 15 minutes. All injured animal groups significantly reduced their 
average speed by day 14 (p<0.004; Figure 11). At day 28, all the injured animals showed a 
reduction in average speed. However, the vehicle and minocycline treatment groups were 
the only groups that demonstrated a significant decrease in average speed compared to 
baseline (p<0.001). At day 42, two weeks post-treatment, the vehicle and minocycline 
groups still demonstrate a significant decrease in average speed compared to baseline 
(p<0.004). At day 60, ten days after the dosing regimen ended, all injured animal groups 
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significantly increased in average speed compared to day 14 (p<0.003). The average speed 
of the naïve group was consistent over time and had no significant changes.  
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Figure 11 Total Average Speed: All injured animals had significantly reduced average 
speeds after injury and all groups significantly improved their speeds by day 60. Error 
bars display the mean ± SEM. [(*) p<0.004 vs. baseline; (†) p <0.005 vs. naïve; (#) p 
<0.003 vs. day 14/28] 
 
During the 15 minutes that the animals were in the activity box chamber, the software 
calculated the total amount of time the animals were at rest in seconds. The amount of time 
that each animal was active was then calculated. The naïve animal group displayed no 
significant changes throughout each of the testing sessions. All injured animal treatment 
groups were significantly less active at day 28 (p<0.002; Figure 12). By day 60, all injured 
animal treatment groups were significantly more active when compared to day 28 
(p<0.003).  
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 Figure 12 Total Active Time: All injured animals displayed a significantly decreased 
amount of time spent active post-injury at day 28. At day 60, ten days after treatment was 
stopped, all injured animals significantly increased their time spent in an active state 
compared to day 28. Error bars display the mean ± SEM. [(*) p<0.002 vs. baseline; (†) p 
<0.005 vs. naïve; (#) p <0.003 vs. day 14/28] 
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 The PAS software calculated the total amount of ambulatory movements or total gait 
made by each animal within the 15 minutes. The naïve un-injured animals displayed 
consistent gait at each testing session and no significant changes were found, as expected. 
After injury, all SCI animal groups significantly decreased the total amount of ambulatory 
movements at day 14 and day 28 (p<0.002; Figure 13). After treatment (day 42 and day 60), 
there were no significant improvements in the amount of ambulatory movements made by 
any treatment group.  
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Figure 13: Total Ambulatory Movement: All injured animals had significantly reduced 
ambulatory movement after injury at day 14 and day 28. There were no significant 
improvements in any SCI animal group post-treatment. Error bars display the mean ± SEM. 
[(*) p<0.002 vs. baseline; (†) p <0.003 vs. naïve] 
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 The PAS software calculated the total amount of rearing events or amount of times 
the animals stood on their hind limbs. The naïve un-injured animals had a significantly 
decreased amount of rearing events at day 28, 42 and 60 (p<0.005; Figure 14). All injured 
animal groups displayed a significantly decreased amount of rearing events after injury at 
day 14 and day 28 (p<0.005). The minocycline group maintained a significantly reduced 
amount of rearing events throughout day 60 (p<0.005). At day 42, after 2 weeks of 
treatment, the gabapentin group significantly increased the total amount of rearing events 
compared to day 14 (p<0.001). At day 60, ten days after gabapentin treatment was complete 
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(washout period), the total number of rearing events remained significantly higher compared 
to day 14 (p<0.001). 
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Figure 14 Total Rearing Events: A significant decrease in rearing events occurred after 
injury in all SCI animal groups at day 14 and 28. There was no significant improvement 
in the vehicle and minocycline group post-treatment. Gabapentin significantly increased 
the total number of rearing events at day 42 and day 60. Error bars display the mean ± 
SEM. [(*) p<0.002 vs. baseline; (†) p =0.001 vs. naïve; (#) p =0.001 vs. day 14 
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Adverse Side Effects 
 
The original study paradigm included a 4-week dosing regimen of 50 mg/kg via i.p. 
injections of minocycline. However, minocycline produced concerns approximately two 
weeks after treatment began. Minocycline treatment via i.p. administration began producing 
sores around the injection sites even with sufficient rotation of appropriate injection sites in 
the left, right and center abdominal areas. There were no visible sores in the vehicle-treated 
animals receiving daily i.p. injections of 3 mL of saline. Therefore, I decided to conclude 
treatment of minocycline after three weeks of administration instead of the full 4 weeks as 
laid out in our original study paradigm. This resulted in the development of aim 2 of this 
study, using the ten day washout period before day 60 testing to determine if any lasting 
effects at reducing pain were maintained.  
 The body weights of all treated animals were monitored throughout the dosing regimen. 
The minocycline-treated animals displayed abnormally low weight gain when compared 
with the gabapentin and vehicle-treated animals (Figure 15). By the end of the 3rd week of 
daily dosing the gabapentin-treated animals had gained an average of 23 grams compared to 
their weight at the end of week one dosing and the vehicle group had gained an average of 
16 grams. However, the minocycline-treated animals had only gained an average of 2 grams 
over the same time period. 
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Figure 15 Average weight gain After 3 weeks of monitoring weight and daily dosing, 
minocycline treatment caused abnormally low weight gain (average= +2 grams) compared 
to the saline treatment (average= +16 grams) and the gabapentin treatment (average=+23 
grams). 
 
After completion of all behavioral assessments, the animals were sacrificed and a trans-
cardial perfusion was properly performed using buffered-saline with heparin followed by 
4% paraformaldehyde. During this procedure, I noticed a remarkable difference in the livers 
of the minocyline-treated animals compared to the gabapentin and saline-treated animals 
(Figure 16A, 16B and 16C). Therefore, the livers were collected (n=1, per treatment group) 
and properly stored. Histology and immunohistochemistry techniques were performed for 
analysis.  
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Figure 16: (A) Gross anatomy of a vehicle treated animal liver; (B) Gross anatomy of a 
gabapentin treated animal liver; (C) Gross anatomy of a minocycline treated animal liver 
displaying an obvious increase in fibrous tissue.  
 
Because of the obvious increase in fibrous tissue on the exterior surface of the 
minocycline treated animal liver, 30 µm sections of the liver were cut on a cryostat for 
subsequent staining procedures. To determine if minocycline caused liver damage I first 
performed a hematoxylin and eosin (H & E) stain. Hematoxylin stained the nuclei blue, and 
eosin stained the cytoplasm and extracellular proteins pink (Figure 17A, 17B, 17C). The 
livers of the saline and gabapentin-treated animals appear to have equally spaced cellular 
structure whereas the liver of the minocycline-treated animal appears to have abnormally 
increased cellular density and thickening near the exterior surface in the upper right quadrant 
of the tissue section.  
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Figure 17: 4x image of H&E stain (A) saline-treated animal liver; (B) gabapentin-treated 
anima liver; (C) minocycline-treated animal displaying increased cellular density and 
thickness toward the exterior surface in the upper right quadrant. Scale bars= 500µm 
 
 
 In order to gain a better understanding of what was developing in the minocycline- 
treated rat liver, I decided to stain sections with a trichrome stain. The trichrome stain 
provides more detail of structures by staining nuclei black, staining cytoplasm of 
hepatocytes red and staining collagen and mucin bright blue. The extent of liver fibrosis in 
patients can usually be determined after a biopsy with a trichrome stain coupled with H&E 
stain (86). The results of the trichrome stain indicate there is a massive amount of collagen 
on the exterior surface of the liver in the minocycline-treated animal (Figure 18C). The 
collagen, indicated in blue, also appears to be infiltrating deep into the liver tissue. There 
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was no abnormal collagen expression found on the exterior of the liver in the saline and 
gabapentin-treated animals (Figure 18A and 18B). 
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Figure 18: 4x image of Trichrome stain (A) saline-treated liver; (B) gabapentin-treated 
liver; (C) minocycline-treated liver displaying large collagen deposits on the exterior 
surface and infiltrating into the tissue. Scale bar=500µm 
 
 The minocycline-treated animal liver showed obvious signs of health problems 
characterized by abnormally low weight gain during treatment and liver fibrosis. In order to 
determine if minocycline caused inflammation in the liver I decided to perform 
immunohistochemistry with a known pro-inflammatory cytokine, Interleukin 1-beta (IL1-β). 
During acute and chronic stages of inflammatory response caused by many types of injury 
and disease, monocyctes and macrophages release IL1-β (87). The results of the IL1-β 
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immuno-fluorescence labeling indicated that there was no IL1-β expression found in the 
saline and gabapentin-treated animal livers (Figure 19A and 19B). However, I identified a 
substantial up-regulation of IL1-β expression that was widespread in the minocycline-treated 
animal liver section visible by labeling with bright green fluorescence in Figure 19C.  
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Figure 19:  10x image of immuno-labeling with pro-inflammatory cytokine, IL1β (A) saline- 
treated animal liver; (B) gabapentin-treated animal liver; (C) minocycline-treated animal 
liver displaying substantial expression of IL1-β. Scale bar=250 µm 
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In order to determine if the positively labeled IL1-β cells in the minocycline-treated 
animal liver infiltrated due to an inflammatory response or simply resident cells, I decided to 
label the tissue with markers for IL1-β and ED-1. ED-1 is a marker of activated 
macrophages. Macrophages are known to migrate to sites of inflammation where they 
activate and release a host of cytokines and toxic radicals to remove debris and kill invading 
pathogens (88).  IL1-β expression co-labeled with ED-1 would further explain that 
minocycline caused an infiltrating, inflammatory response leading to hepatoxicity. The 
results indicated that IL1-β was highly co-localized with ED-1 in the minocycline-treated 
animal liver (Figure 20). 
                                
Figure 20: 20x image immuno-label using ED-1, a marker of activated macrophages, in 
liver of minocycline-treated animals. ED-1 (red) is highly co-localized with immuno-
labeling of IL1-β a pro-inflammatory cytokine in green. Scale bar=100 µm 
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  DISCUSSION 
 The purpose of this study was to investigate the potential therapeutic benefit of long-
term minocycline administration to attenuate or abolish established CNP after SCI. I 
performed a series of pre-clinical pain behavior assessments in a rodent model of SCI. First, 
I focused on determining if a two week dosing regimen of minocycline (50mg/kg) could 
attenuate established CNP. I then determined if a ten day washout period of the drug would 
reduce CNP long-term. Finally, I compared the efficacy and safety of minocycline with the 
current “gold standard” of treatment, gabapentin. I hypothesized that long-term 
administration would decrease established CNP following a severe contusion SCI in a 
rodent model.  
Minocycline 
I found that systemic minocycline treatment attenuated established neuropathic pain in 
rats following spinal cord injury. This treatment is in accordance with the precedent set by 
several pre-clinical studies that showed an attenuation of SCI-induced pain with acute 
treatment of minocycline administered shortly after injury (46),(65),(66),(67),(62),(28),(39).  
Previous studies have focused on early intervention for neuropathic pain after SCI with 
minocycline treatment administered shortly after the SCI. While the ability to suppress CNP 
before it can become established will provide hope to those who encounter an SCI in the 
future, it should be noted that there are many individuals living in the chronic phase of SCI 
and approximately 65% have established CNP (89).  
This study focused on finding a therapeutic intervention for reducing or stopping 
neuropathic pain long after establishment. The study focused on providing knowledge that 
could potentially benefit thousands of individuals who are enduring CNP many years after a 
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traumatic SCI event. A pre-clinical SCI study by Hains and Waxman showed that a brief, 
three day treatment regimen with minocycline could attenuate established neuropathic pain 
in rats 30 days post-SCI. However, the pain returned immediately after treatment was 
stopped (36). This study is the first to show that it was possible to reduce established CNP 
via long-term administration of minocycline in both below-level mechanical allodynia of the 
hind paws and hyperalgesia above the level of injury.  
I observed no significant reduction in below-level hyperalgesia after two weeks of 
minocycline treatment. The animals may have experienced pain on the torso area below the 
level of injury. However, an alternative explanation is that pain levels remained high due to 
application of a noxious force near the sites of irritation caused by i.p. injections.  
I also observed that there were no significant improvements in exploratory behavior such 
as distance, speed and active time after two weeks of minocycline administration. 
Spontaneous, exploratory behavior can be used to measure pain-like behaviors in an 
indirect, non-evoked manner because animals in pain move less (84). Measuring pain in 
animals is a difficult task not only because of the complexities of CNP development, but 
also because of the inability to define pain in animal subjects that correlates to all the pain 
modalities experienced by SCI patients. The photobeam activity box software may help us 
to identify symptoms of non-evoked pain or pain where no peripheral stimulus exists. Non-
evoked pain is a major contributor of severe CNP in humans (89),(90),(91).   
After injury, the animal subjects displayed a significant decrease in spontaneous 
behavior such as distance, average speed, active time, ambulatory movement and rearing. 
Therefore, any significant improvements in spontaneous behavior after treatment could be 
associated with a decrease in overall pain. The minocycline treatment group followed the 
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same trend as the vehicle treatment group when comparing distance moved, average speed 
moved and amount of time spent active over time. I found a significant decrease in 
ambulatory movement and rearing events compared to the baseline that also followed the 
same trend of the vehicle treatment group. This data suggests that overall pain may still have 
affected the minocycline and vehicle-treated animals post-treatment.  
The lack of improvement in exploratory behavior after two weeks of minocycline 
treatment could be due to gut irritation from repeated i.p. injections and possible toxicity 
problems as previously described. The sores caused a great restriction in hind limb motor 
movement that did not allow the animal to have proper locomotor function while on the 
dosing regimen. It was unclear whether the observations were due to a continuing 
phenomenon of CNP, from irritation of the i.p. injections or from toxicity due to the 
treatment schedule. In future studies with long-term minocycline administration it will be 
important to use a different mode of administration and an alternative schedule for long-term 
dosing to rule out issues caused by i.p. injection and toxicity.  
Despite the discrepancy in the activity box data most of the suppressed behavioral trends 
while on the minocycline dosing regimen improved by day 60 testing. The sores caused by 
repeated i.p. injection healed after the ten day washout period of the drug and the trends in 
distance, speed, active time, ambulatory movement and rearing events improved compared 
to day 42. This suggested that the animals may have recovered a portion of their locomotor 
function that was previously restricted due to the i.p. injections. It was also possible that the 
animals were experiencing less pain because the wounds were healed. However, due to 
improving trends in all of the same behavior assessments in the vehicle treatment group, this 
remained unclear. Overall improvements in locomotor function and behavior activity in the 
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vehicle treatment group suggested that there was an obvious, naturally occurring 
improvement in the Sprague-Dawley rat model of SCI, 60 days post-injury.  
This study was the first to discover that minocycline had a lasting effect in reducing 
CNP after SCI. I found that even after the ten day washout period of minocycline, below-
level mechanical allodynia and above-level hyperalgesia significantly diminished. The half-
life of minocycline in rodents is approximately two to three hours which means the drug is 
completely out of their system by day 60 testing following a final dose at day 50 (92). I 
found that minocycline produced a sustained reduction in CNP, and this contradicts  
previous findings by Hains and Waxman who showed that pain returned immediately 
following withdrawal of minocycline (36). Hains and Waxman tested minocycline with a 
three day regimen of twice daily injections (100 ug/5 ul) intrathecally while I administered 
minocycline a total of three weeks intraperitoneally (36). The two different modes of 
administration vary greatly. An intrathecal dose involves an intrathecal catheter placed in the 
lumbar enlargement of the animal subject and correlates to an intrathecal injection in 
humans where a drug can be delivered into the fluid cavity surrounding the spinal cord (93). 
This method has the disadvantage of being an extremely invasive procedure. However, the 
intrathecal delivery method eliminates the concern that the drug will not pass the blood-
brain-barrier by making the injection directly into the spinal cord. For example, SCI patients 
received continuous administration of baclofen, a drug that specifically targets Gamma-
aminobutyric acid (GABA) receptors within the spinal cord, by an implanted intrathecal 
pump (94). This method was not only safe; it was significantly more effective than an oral 
dose and required a dose amount that was 100-fold less than an oral dose (94). 
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Intraperitoneal injections place the potential therapeutic directly into the intraperitoneal 
space in the lower abdominal area with caution to avoid contacting any organs. The 
advantage of i.p. administration is that it is the most widely used method in rodents for safe, 
systemic delivery of drugs (95). However, it does not correlate well to humans. Currently, 
clinicians are only using intraperitoneal injections for delivery of several chemotherapy 
agents(96). However,  they are highly controversial because of the risk of complications and 
toxicity (96). Overall, the differences in the mode of administration in animal subjects can 
vary greatly and can cause differences in outcome, efficacy and side effects. It is most 
important to deliver the drug in a safe and tolerable manner in the animal subjects to ensure 
that the drug is able to target the intended mechanisms of action effectively.  
The possible mechanisms by which minocycline administration could attenuate CNP is 
still unclear, however there are several interesting CNP mechanisms that it may target. A 
robust immune response followed by inflammation of the tissue surrounding the injury is a 
prolonged pathological event after SCI that contributes to CNP (42),(21). Minocycline is 
considered a multi-target or “dirty” drug because aside from antibiotic properties, it also 
targets the inflammatory response through the inhibition of microglia activity (36),(39),(97) 
(98). Microglia cells within the spinal cord normally remain in an inactive/resting state to 
maintain architecture and homeostasis of neuronal cells (41). After SCI, microglia cells 
activate, display “ramified branches” and release pro-inflammatory cytokines (41),(36). 
Fleming-Norenberg et al. reported that activated microglia were abundant up to one-year 
post-SCI in humans (20). Activated microglia cells produce an ongoing inflammatory 
response that correlates with maintenance of CNP (42),(43),(36),(44). Inhibition of 
microglia activation by minocycline administration reduces the production of pro-
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inflammatory cytokines such as TNF-α, IL-β, IL-6 and prostaglandin-E2 (PGE2) that 
contribute to the continuation of pain (98). Minocycline inhibits matrix metalloproteinases 
(MMPs) activity, which reduces inflammation and prevents tissue remodeling (60). After 
SCI, MMPs become activated; exhibiting enzymatic activity that breaks down extracellular 
matrix components. While a crucial activity for permitting angiogenesis, MMP activation 
also contributes to inflammation and tissue damage within the spinal cord (60). Minocycline 
also inhibits apoptosis by inhibiting cytochrome c release from the mitochondria, an initial 
step in the signaling of the apoptosis cascade (61),(62). Inhibition of apoptosis prevents cell 
death, spares tissue around the spinal cord and contributes to an overall neuroprotective 
environment (67),(62),(66),(65).   
Due to minocycline’s ability to target the immune response, I must also be aware that 
the wounds from repeated i.p. injections may have been prevented from healing. The 
wounds depend upon the immune system’s ability to heal efficiently. However, minocycline 
may inhibit the immune cells necessary for wound healing which, in this model, may have 
delayed the healing process. Overall, the finding suggested that long-term i.p. administration 
of minocycline at 50 mg/kg had a lasting effect of reducing some symptoms of CNP after 
SCI. While this study is not mechanistic in nature, I am intrigued by the possibility that 
sustained minocycline treatment may exert a sustained reduction in pain through modulation 
of known inflammatory mechanisms. This question will be addressed in subsequent studies.  
Minocycline vs. Gabapentin 
Gabapentin (Neurontin ®) is the current “gold standard” drug prescribed for the 
treatment of CNP in chronic SCI patients.  The use of gabapentin includes multiple adverse 
side effects that include dizziness, somnolence and nausea (52).  It has been well-established 
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that gabapentin has the ability to transiently reduce symptoms of CNP (99). Yet many 
clinicians are seeking alternatives to gabapentin due to adverse side effects. Patients who use 
gabapentin as a treatment for CNP often complain that it provides inadequate pain relief and 
also causes a multitude of adverse side-effects that make it difficult to function in daily life 
(53),(52). In order to determine the potential of minocycline to replace gabapentin as a 
standard of treatment for CNP I focused on comparing the efficacy and safety of both drugs. 
The results indicated that gabapentin reduced below-level mechanical allodynia after 
two weeks of daily dosing with 50 mg/kg via subcutaneous injections. This concentration of 
gabapentin was chosen based on a previous study by Hama and Sagen who found that 50 
mg/kg effectively reduced CNP after SCI in a rodent model (75). Minocycline is equally as 
effective at reducing below-level allodynia at this time point, which provided further 
evidence that minocycline could be a potential new therapeutic intervention for CNP.  
Gabapentin treatment reduced below-level mechanical allodynia at day 60 testing, ten 
days after withdrawal of gabapentin. The data suggested that the reduction in pain was long-
term because the effects were still significant ten days after gabapentin treatment ceased. 
Gabapentin has a very short half-life in rodents of 1.7 hours (100). Therefore, I expected 
pain levels to return by day 60 testing.    
I observed no reduction in above-level hyperalgesia in the gabapentin treatment group 
using the girdle response test. This is in contrast to my finding that minocycline treatment 
significantly reduced pain at this level. The data suggested minocycline may effectively 
reduce symptoms of hyperalgesic pain above the level of injury that gabapentin cannot and 
that there may be different mechanisms responsible for above level pain compared to below 
level pain which should be further explored.  
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Gabapentin treatment significantly diminished below-level hyperalgesic pain whereas 
minocycline treatment did not. Interestingly, the reduction of pain was observed during day 
60 testing, ten days after dosing was complete. I did not expect to see a significant decrease 
in below-level hyperalgesia after a ten day washout period because of gabapentin’s short 
half-life. Therefore, long-term gabapentin treatment may have a lasting effect at reducing 
below-level hyperalgesia in a rodent model of SCI.  
 I found a significant increase in pain at day 42, while the animals were on the dosing 
regimen of gabapentin. The significant increase in below-level hyperalgesia could be 
explained by the mode of administration. Subcutaneous injections were made in the same 
areas where the application of the filaments was placed on the torso. Therefore, the 
significant increase in pain at day 42 could be explained by hypersensitivity caused by the 
mode of administration causing pain or irritation on the animal’s lower torso area. This may 
also explain why there was no reduction in above-level hyperalgesic pain using the girdle 
response test after gabapentin treatment.  The results suggested that gabapentin may have 
had a lasting effect at reducing below-level hyperalgesia and below-level allodynia. The data 
is in contradiction to the current literature that demonstrates that neuropathic pain levels 
return shortly after withdrawal of gabapentin treatment in a rodent model of SCI (101).  
In addition to the unexpected findings after the washout period, I also observed a lasting 
improvement in the behavioral activity data. Total distance significantly increased at day 42 
and day 60 in the gabapentin treatment group whereas the minocycline group continued to 
decrease. The vehicle treatment group also significantly increased total distance at day 60 
indicating that the natural improvement over time most likely accounted for the 
improvements with total distance, average speed and active time.  
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Interestingly, gabapentin treatment significantly improved the number of rearing events  
within the activity box over the 15 minute period. I did not observe this in any other 
treatment group. Gabapentin-treated animals demonstrated a significant increase of rearing 
events at day 42 and after the ten day washout period at day 60. This is the first study to 
show that long-term gabapentin treatment could increase the number of rearing events after 
an extended washout period in a rodent model of SCI. This suggested that gabapentin 
provided long-lasting relief at reducing below-level pain, which allowed the animals to feel 
more comfortable standing up on their hind limbs. However, the increase in rearing events 
could also indicate that the animals had more homeostatic control over their muscles and 
therefore, improved trunk stability. It could also mean that perhaps gabapentin treatment 
reduced secondary injury and improved motor function recovery after SCI in the animal 
model.  
Gabapentin treatment may improve trunk stability or provide neuroprotection and 
prevent secondary injury by an unknown mechanism. Recently, a single dose of gabapentin 
(200mg/kg or 30mg/kg) administistered immediately after injury in a rabbit model of spinal 
cord ischemic injury significantly protected the ultrastructure of the spinal cord (102). This 
study suggested that a single dose of gabapentin immediately after ischemic injury could 
have neuroprotective effects. Likewise, a pre-clinial study demonstrated that  a single dose 
of gabapentin (200mg/kg or 30mg/kg) in a rat model of SCI demonstrated significant 
neuroprotective characteristics by examination of spinal cord tissue and plasma levels (103). 
Perhaps long-term gabapentin treatment was administered at an oportunistic time window 
post-injury in my study that provided neuroprotective effects and reduced secondary injury 
and increased motor recovery of the hind limbs.  
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 Additionally, a recent study also demonstrated that gabapentin significantly reduced 
symptoms of muscle spasticity and autonomic dysreflexia with a single dose of gabapentin 
(50 mg/kg, i.p.) in an SCI rodent model when measured between 2 and 3 weeks after injury 
(12). Autonomic dysreflexia is a severe and painful condition characterized by a rapid attack 
that causes an enormous increase in blood pressure, shivering, sweating, anxiety and severe 
headaches (13).  
Muscle spasticity and intense, painful muscle spasms are common complaints among 
SCI patients (12). Abnormal somatic and autonomic motor reflexes are thought to be the 
cause of symptoms associated with muscle spasticity and autonomic dysreflexia after SCI 
(12). In 1997, Gruenthal et al. performed a clinical trial to test if (2,400 mg over 48 hours) 
gabapentin treatment could reduce muscle spasticity in SCI patients. The authors concluded 
that gabapentin treatment significantly decreased muscle spasticity, which consequently 
improved the patients’ overall quality of life (104). Gabapentin may diminish the somatic 
and autonomic motor reflex pathways by inhibiting glutamate release at presynaptic 
terminals in neurons (12). In my model of SCI, long-term gabapentin treatment may have 
produced similar effects. By reducing muscle spasticity with gabapentin treatment, this 
could explain why the animals had an increase in rearing events and perhaps long-term 
gabapentin treatment could contribute to more homeostatic control of muscles or increased 
muscle tone. 
The currently accepted  mechanism of gabapentin is its ability to binds to a calcium 
channel subunit, alpha-2-delta, and reduce calcium influx into cells (49),(50),(51). This 
decreases excitability of neurons (49),(50),(51). Decreasing the excitability of neurons by 
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inhibiting transmitters such as glutamate and substance-P provides an analgesic effect 
(50),(51). However, I propose that gabapentin treatment and its mechanisms of action should 
be further investigated for its potential as an early intervention after SCI to prevent or reduce 
symptoms that develop into chronic conditions such as neuropathic pain, muscle spasticity 
and autonomic dysreflexia. Taking into account all of the unexpected improvements 
demonstrated after the washout period and the significant increase in rearing events, not 
only does long-term gabapentin-treatment reduce pain; it may also beneficially target 
additional mechanisms that lead to permanent changes and muscle tone and recovery after 
injury.   
Additionally, I measured pain by application of von Frey hair filaments. However, I 
cannot rule out the possibility that an intense flinch reaction above or below the level of 
injury using the girdle test may instead be an intense reflex reaction in our animal model. 
Likewise, I cannot rule out the possibility that a quick withdrawal of the hind paw using the 
von Frey hair test may instead be an intense reflex reaction.  Provoking a reflex reaction 
instead of pain would indicate the animals are experiencing increased muscle spasticity and 
application of filaments on the hind limb and hind paw were simply inducing a severe 
muscle spasm. Recent studies suggest that this may be the case when measuring 
hypersensitivity below the level of SCI. Baastrup et al. reported that when measuring below-
level pain in a rat model of SCI  there was no indication of an increase in brainstem reflexes 
or unpleasant behavior which would be indicative of pain development as it correlates to 
humans (105). They concluded that they were simply measuring spinal reflexes and that 
measuring spinal reflexes is most likely not an appropriate measure for studying below-level 
pain development in rodents (105). Likewise, Urban et al. reported in a recent pre-clinical 
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study on mice that measuring mechanical hypersensitivity may not adequately measure 
chronic pain because they did not find any significant behavior changes such as increased 
anxiety, depression or changes by examining home cage behaviors which would indicate a 
decrease in quality of life compared to control animals (106).  They indicate that depression 
and an alteration in daily activities in human patients living with chronic pain is a relevant 
and critical feature of chronic pain and that the mice did not develop these qualities which 
would indicate chronic pain development (106). 
Therefore, my data could also suggest that gabapentin and minocycline may 
specifically target mechanisms underlying muscle spasticity and motor recovery after SCI 
instead of pain. Several studies indicate that acute minocycline treatment improves hind 
limb motor recovery weeks after injury using the BBB test and that minocycline has a 
neuroprotective effect after injury (66), (62),(67),(65). Therefore, minocycline could also 
improve motor recovery and decrease muscle spasticity with long-term administration and 
needs to be explored with additional, more rigorous assessments of motor function in 
subsequent studies.  
Adverse Side Effects 
I found several unexpected, negative side effects caused by a three week daily dosing 
regimen of 50 mg/kg minocycline administration via i.p. injections. The minocycline 
treatment group demonstrated abnormally low weight gain when compared with the other 
treatment or vehicle groups. Because this was the first assessment of a delayed, long-term 
dosing regimen of minocycline in an early chronic rat model of SCI, the toxicity levels were 
uncertain. One explanation for the low weight gain could be due to the antibiotic properties 
of minocycline. However, it is unclear whether antibiotics such as minocycline can cause 
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decreased appetite. In contradiction to our findings recent evidence suggests that extensive 
use of antibiotics including minocycline, may actually cause weight gain in patients (107). 
Therefore, the abnormally low weight gain in the minocycline treatment group could be 
indicative of signs of toxicity. I must consider that the dosing-schedule, concentration (50 
mg/kg) and/or mode of administration (i.p.) were the cause. A wide range of pre-clinical 
studies of CNS trauma and disease have used concentrations of minocycline ranging from 
10-100 mg/kg (28),(62),(67),(66),(65),(46). However, pre-clinical studies in rats using the 
i.p. delivery route have shown efficacy in improving functional recovery and attenuating 
pain with only acute treatment of minocycline. These acute studies range from a single dose 
to a maximum 5 day dosing regimen with concentrations ranging from 45 mg/kg to 180 
mg/kg (28),(62),(67),(66),(65),(46). This was the first study to show complications of long-
term minocycline administration via i.p. injections in a Sprague-Dawley rat model of SCI.  
In addition to abnormally low weight gain, long-term i.p. injections caused extensive 
chemical burns and sores around the sites of injection in the abdominal area. This is 
consistent with the findings by Nessler et al. who discussed a concern that the effects of 
minocycline treatment causing abdominal irritation with repeated dosing of 100 mg/ml i.p. 
injections in a rat model of autoimmune encephalomyelitis (108). Additional research would 
be advantageous for understanding the proper mode of administration and correct 
concentration of minocycline in a rat model of SCI as an important step to assess efficacy 
prior to clinical translation. A pre-clinical assessment utilizing several modes of 
administration such as intrathecal, oral gavage and intravenous would provide further 
evidence as to which method is the most efficacious in the SCI rat model. Discovering the 
proper mode of administration in animal subjects is critical for effective translation into 
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clinical trials. Intraperitoneal injections (i.p.) have little relevance to translation in humans 
except for chemotherapy delivery, whereas intrathecal, oral gavage and intravenous 
injections are not only relevant, they can help determine the safest and most effective 
delivery method for patients. In addition, I further recommend performing a pre-clinical 
dose-response test to determine the optimal dose of minocycline that would effectively 
decrease CNP and minimize the negative side effects. Finally, my data suggested that a 
reduction in pain may be possible beyond the cessation of treatment. If this is the case, it 
will be important to determine the shortest possible time period for delivery of minocycline 
to elicit a long-term reduction in CNP while preventing or minimizing the adverse side 
effects observed with long-term minocycline treatment. 
I observed a pronounced cellular inflammatory response in the livers of minocycline-
treated subjects that suggested the onset of minocycline treatment-dependent hepatoxicity. 
Hepatoxicity is defined as drug-induced liver injury and is often difficult to diagnose in 
patients (109). My observations indicated that hepatoxicity may have occurred in the 
minocycline-treated subjects. This may have been due to the observed increase in collagen 
production as well as the presence of macrophages, many of which co-localize with the pro-
inflammatory cytokine, IL1-β. There are several reports of hepatotoxicity in pre-clinical SCI 
studies using minocycline. It is unclear if the liver damage observed in my study was due to 
long-term administration or because of the route of minocycline administration. Some 
damage to the liver could be due to the close proximity of the liver to the area in which the 
drug was administered. Minocycline is a drug soluble in a weak acidic solution (pH 5) that 
may have affected not only the abdominal epidermis but also organs near the injection sites 
(92). Interestingly, my results are in agreement with many human case studies that found 
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evidence of liver damage with long-term use of minocycline. This suggests that the liver 
damage I observed may not have been caused by i.p. injections alone. Autoimmune hepatitis 
and liver damage from tetracycline antibiotics such as minocycline are reported in patients 
after an average use of two years (69),(68). Additionally, SCI patients could be predisposed 
to autoimmune hepatitis or liver disease due to their injury alone and minocycline could 
greatly increase their chances of developing hepatoxicity. Researchers and clinicians are 
discovering that SCI may cause decreased metabolic function, or function of the liver, due to 
recent evidence found in pre-clinical models of SCI and  in patients with SCI (110),(111). 
Research studies focusing on the degree of metabolic dysfunction and drug-induced liver 
damage in a rodent model of SCI would be very helpful in determining a patient’s benefit-
risk ratio of taking drugs known to cause hepatoxicity. In future studies it will also be 
important to identify the minimal dose of minocycline required to reduce pain long term 
while also minimizing toxicity.  
 
Limitations 
 The study of pain in animals is very difficult because pain is a highly subjective 
sensory interpretation. The tests developed and used in my study to measure pain were 
developed based on the assumption that the stimulus applied to an animal will evoke pain 
much like it does in humans. I measured mechanical hypersensitivity of the hind paws with 
the use of von Frey filaments with increasing force which correlated to peripherally-evoked 
mechanical allodynia in humans. I measured hypersensitivity of the torso using the girdle 
test which correlates to peripherally-evoked hyperalgesia and allodynia of the torso in 
humans. Finally, I measured spontaneous behavioral activity of the animal subjects to 
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perhaps provide better insight into the development of non-evoked pain or spontaneous pain 
which correlated to the development of spontaneous/non-evoked neuropathic pain in 
humans. SCI patients experience spontaneous neuropathic pain with sensations described as 
burning and pricking usually at or below the level of injury (90). Phantom pain is 
spontaneous pain that does not require a peripheral stimulus and occurs where there is total 
sensory loss (90). I  also cannot rule out the possibility that the von Frey hair filaments are 
simply evoking a reflex response instead of pain as previously described. Determining 
whether the pain behavior tests used in rodents acccurately measure pain or instead measure 
muscle spasticity would greatly impact the field of study on neuropathic pain.  
 I did not measure thermal sensitivity of the hind paws in the animal subjects.  
Thermal sensitive testing in animal subjects correlates to thermal sensitivity in SCI patients 
who often experience a significantly increased response to hot and cold temperatures, most 
often above the level of injury (112). I also did not use the Randall-Selitto test which 
measures nociceptive withdrawal threshold of the dorsal and plantar surfaces of the paws by 
applying an increasing amount of force with an electronic algesimeter until the animal 
withdrawals the paw (113). Recently, Santos-Nogueira et al. used the Randall-Selitto test to 
measure neuropathic pain in animal models of both spinal cord contusion and transection 
injury (114). They found that the test was a sensitive and adequate measure of neuropathic 
pain in the animal subjects and  that earlier time points could be tested compared to the von 
Frey hair test because weight support was not required (112). In future studies, it would be 
beneficial to combine behavior testing with developed diagnostic and physiological 
measures of pain in animals. The lab of Dr. Raymond Grill is currently developing an 
approach to discern evoked verses non-evoked pain using non-invasive functional MRI.  
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Based on my results there was high variability in the amount and types of 
neuropathic pain each animal experienced that I believe correlated well with studies on 
neuropathic pain in humans. Pain prevalence data after SCI is difficult to gather and analyze 
due to the many classifications and ways of identifying neuropathic pain in humans (7).  In 
my study, some animals developed increased sensitivity to the mechanical allodynia test 
while other animals only developed sensitivity in the hyperalgesia test. Using several testing 
procedures such as von Frey hair test, girdle test and behavior activity can be beneficial in 
detecting a wide array of pain symptoms. However, it also makes it difficult to decide which 
animals animal subjects to include in the study based on which ones developed significant 
levels of CNP. I developed strict criteria to eliminate animals that did not appear to develop 
pain after injury, which decreased the total number of animals for analysis. In future studies 
that use only behavior tests for outcome measures, it may be useful to develop a strategy to 
analyze each test individually, instead of eliminating animals from all tests that did not show 
pain in only one or two tests. It may be beneficial to use one behavior test to measure overall 
pain and continue to  develop better diagnostic strategies for analyzing neuropathic pain in 
rodent models.  
 The animals are extremely sensitive to the testing environment. It was important to 
test animals in a quiet room with no other animals or people allowed in and to clean the 
testing equipment between each testing session. I moved the location of behavior testing in 
the middle of our study and upgraded the von Frey hair testing apparatus. I did not notice 
any significant differences in behavior due to these changes.   
Additionally, I observed hyper-sensitization in the naïve un-injured group. Animals 
are known to produce a “fear scent” if they are in pain, startled or afraid which could cause 
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other animals to become stressed (85). The naïve animals may have detected a fear scent 
released by the injured animals due to pain and distress from their injuries. In future studies, 
it would be beneficial to test the naïve un-injured animals separately from the injured 
animals to prevent hypersensitivity in the naïve group. 
The girdle test was used to measure sensitivity of the torso area. However, the 
animals were rapidly growing in length and girth over the course of the study and changes in 
the size of the restraint devices were made over time. This made it difficult to apply the von 
Frey filaments in a consistent location at each testing session. Additionally, some animals 
became noticeably anxious even after being allowed to acclimate to the device before each 
testing session. Therefore, some animals may have flinched or vocalized due to the stress 
and anxiety of being secured in a small restraint device instead of actually experiencing 
provoked neuropathic pain or muscle spasms.   
This was not a completely blind study. I divided the animals into treatment groups at 
day 29, which means that baseline, day 14 and day 28 testing were blind and day 42 and day 
60 were not. After dosing, animals were divided into treatment groups, and behavior testing 
and dosing was performed by one person. It is beneficial to have only one person 
performing all behavior tests because some testers will be more stringent than other testers. 
In future studies it would be ideal to have two people perform behavior tests and then 
average the results of both raters. 
Finally, another limitation of this study is that I was only able to look at one 
concentration of minocycline for long-term treatment. The dose concentration of 50 mg/kg 
used in this study is an average dose commonly used in rodents, as the dosing ranges from 
10 mg/kg to 180 mg/kg in most pre-clinical studies of minocycline. The dose concentration 
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in humans is approximately 2-3 mg/kg (58). Therefore, minocycline administration is at a 
much higher concentration in pre-clinical rodent studies than the common human dose 
concentration. This makes translation into clinical trials difficult due to the adverse side 
effects I observed with the dosing regimen tested, despite the fact that it is an FDA approved 
drug. Perhaps a lower dose of minocycline would be sufficient to reduce pain without 
causing liver damage. I suggest further pre-clinical testing with minocycline to develop a 
safe mode of administration for long-term use while also performing a dose response test to 
identify the minimal dose required to achieve significant pain relief. This is particularly 
important in the SCI population as well as other CNS trauma and disease populations that 
may be experiencing decreased metabolic function. 
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CONCLUSIONS 
 
  I have demonstrated that minocycline can attenuate CNP during a long-term dosing 
regimen. Further, the anti-nociceptive effects are sustained following cessation of treatment, 
suggesting that minocycline may have potential as a clinical therapeutic in the treatment of 
SCI-induced CNP.  
 However, long-term use of minocycline in with the  treatment schedule caused 
negative side effects such as gut irritation, low weight gain, and hepatotoxicity that need to 
be addressed with further pre-clinical studies. Using a lower concentration, different dosage 
schedule and different modes of administrations such as oral gavage may reduce the side 
effects I observed.  
Gabapentin treatment caused a significant and sustained reduction in CNP ten days 
after withdrawal of treatment. This result was unexpected because gabapentin has a short 
half-life of 1.7 hours in rodents and previous studies have demonstrated that pre-drug pain 
levels return shortly after withdrawal of treatment.  Additionally, the gabapentin-treated 
animals demonstrated a significant and sustained increase in rearing events compared with 
all other treatment groups.  The data suggested that gabapentin treatment was not only 
capable of reducing pain long-term but it may significantly improve trunk stability and 
muscle tone or provide neuroprotection which decreased secondary injury.   
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